Soleus Capital Management, L.P. Uro Gen Pharma Ltd. Transaction History
Soleus Capital Management, L.P.
- $1.29 Billion
- Q2 2025
A detailed history of Soleus Capital Management, L.P. transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Soleus Capital Management, L.P. holds 2,185,000 shares of URGN stock, worth $42 Million. This represents 2.32% of its overall portfolio holdings.
Number of Shares
2,185,000Holding current value
$42 Million% of portfolio
2.32%Shares
3 transactions
Others Institutions Holding URGN
# of Institutions
154Shares Held
38.4MCall Options Held
1.93MPut Options Held
594K-
Rtw Investments, LP New York, NY4.54MShares$87.2 Million0.96% of portfolio
-
Toronto Dominion Bank Toronto, Ontario, A63.19MShares$61.3 Million0.08% of portfolio
-
Morgan Stanley New York, NY2.48MShares$47.6 Million0.0% of portfolio
-
Jefferies Financial Group Inc. New York, NY2.2MShares$42.2 Million0.27% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$42.1 Million0.0% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $437M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...